CO5080731A1 - Compuestos de tetrahidroisoquinolinil-carboxamida y composiciones que los contienen - Google Patents

Compuestos de tetrahidroisoquinolinil-carboxamida y composiciones que los contienen

Info

Publication number
CO5080731A1
CO5080731A1 CO98075174A CO98075174A CO5080731A1 CO 5080731 A1 CO5080731 A1 CO 5080731A1 CO 98075174 A CO98075174 A CO 98075174A CO 98075174 A CO98075174 A CO 98075174A CO 5080731 A1 CO5080731 A1 CO 5080731A1
Authority
CO
Colombia
Prior art keywords
alkyl
formula
cycloalkyl
group
disorders
Prior art date
Application number
CO98075174A
Other languages
English (en)
Inventor
Steven Coulton
Rodercik Alan Porter
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Publication of CO5080731A1 publication Critical patent/CO5080731A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C07D217/04—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C07D217/06—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with the ring nitrogen atom acylated by carboxylic or carbonic acids, or with sulfur or nitrogen analogues thereof, e.g. carbamates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Anesthesiology (AREA)
  • Addiction (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)

Abstract

Un compuesto de fórmula (I) o una sal o solvato del mismo aceptable farmacéuticamente:<EMI FILE="98075174_1" ID="1" IMF=JPEG >en dondeQ es un arilo monocíclico o bicíclico o un anillo de heteroarilo,R1 es hidrógeno, alquilo (C1 -C6 ) (opcionalmente sustituido con hidroxi o alcoxi (C1 -C4 ) (, alquenilo (C1 -C6 ) , alquinilo (C1 -C6 ) alquilo (C1 -C6 )CO-, formilo, CF3 CO- o alquilo (C1 -C6 )SO2 -,R2 es hidrógeno o hasta tres sustituyentes elegidos entre halógeno, NO2, CN, N3, CF3S-, CF3CO-, trifluorometildiazirinilo, alquilo (C1 -C6 ) , alquenilo (C1 -C6 ), alquinilo (C1 -C6), perfluoroalquilo (C1 -C6), cicloalquilo (C3 -C6 ), cicloalquil (C3 -C6 ) alquilo (C1 -C4 ), alquilo (C1 -C6 )O-, alquilo (C1 -C6 )CO-, cicloalquilo (C3 -C6 )O-, cicloalquilo (C3-C6)-CO-, cicloalquil (C3-C6)-alquilo(C1-C4 )O-, cicloalquil (C3-C6)alquilo (C1-C4 )CO-, fenilo, fenoxi, benciloxi, benzoílo, fenil-alquilo (C1-C4)-, alquilo (C1-C6 )S-, alquilo (C1-C6 )- SO2 -, (alquilo (C1-C4 ))2 NSO2 -, (alquilo (C1 -C4 ))NHSO2 -, alquilo (C1 -C4 )) NCO-, (alquilo (C1 -C4))NHCO, CONH2 , CF3 SO2, alquenilo (C1-C6), alquinilo (C1-C6 ) o hidroxialquilo (C1 -C6 ) ;o -NR3 R4 en donde R3 es hidrógeno o alquilo (C1 -C4 ) , y R4 es hidrógeno, alquilo (C1-C4 ) , formilo, -CO2 -alquilo (C1 -C4); o dos grupos R2 juntos forman un anillo carbocíclico que es saturado o insaturado y es no sustituido o sustituido con -OH ó =O; yX es halógeno, alcoxi (C1-C6 ) , alquilo (C1 -C6 ) , alqueniloC2-6 opcionalmente sustituido con fenilo.Un procedimiento para preparar compuestos de fórmula (I) según una cualquiera de las reivindicaciones 1 a 6, que comprende hacer reaccionar un compuesto de fórmula (II)<EMI FILE="98075174_2" ID="2" IMF=JPEG >En la que R1A es R1 como se definió para la fórmula (I) o un grupo convertible R1 y XA es X, como se define en la reivindicación 1, o un grupo convertible en X, con un compuesto de fórmula (III)- 2 -<EMI FILE="98075174_3" ID="3" IMF=JPEG >en la que Q es como se definió en la fórmula (I), Y es Cl o OH, y los grupos R2A son independientemente R2 como se definió para la fórmula (I) o grupos convertibles en R2, y, sí se requiere, convertir un grupo XA , R1A o R2A en un grupo X, R1 o R2 , convertir un grupo X, R1 o R2 , en otro grupo X, R1 o R2 , convertir un producto en forma de sal en la base libre o en otra sal aceptable farmacéuticamente, o convertir un producto en forma de base libre en una sal aceptable farmacéuticamente.Una composición farmacéutica para ser usada en particular en el tratamiento y/o la profilaxis de la ansiedad, manía, depresión, trastornos de pánico y/o agresión, trastornos asociados con una hemorragia subaracnoidea o choque neural, los efectos asociados con la retirada de sustancias de abuso tales como cocaína, nicotina, alcohol y benzodiazepinas, trastornos tratables y/o prevenibles con agentes anticonvulsionantes, tales como la epilepsia , incluyendo la epilepsia post-traumática, enfermedad de Parkinson, psicosis, migraña, isquemia cerebral, enfermedad de Alzheimer y otras enfermedades degenerativas tales como corea de Huntingdon, esquizofrenia, trastornos compulsivos obsesivos (OCD), déficit neurológicos asociados con el SIDA, trastornos del sueño (incluyendo trastornos del ritmo circadiano, insomnio y narcolepsia), tics (p. Ej. Síndrome de Giles de la Tourette), lesiones cerebrales traumáticas, tinnitus (zumbido de oídos), neuralgia, especialmente neuralgia trigeminal, dolor neuropático, dolor dental, dolor oncológico, actividad neuronal inapropiada que resulta en neurodistesias en enfermedades tales como la diabetes, esclerosis múltiple (MS) y enfermedad neuronal motriz, ataxias, rigidez muscular (espasticidad), disfunción de la articulación temporomandibular o esclerosis lateral amiotrófica (ALS), que comprende un compuesto de fórmula (I) según una cualquiera de las reivindicaciones 1a a 6a , o una sal o solvato del mismo aceptable farmacéuticamente, y un vehículo aceptable farmacéuticamente.
CO98075174A 1997-12-17 1998-12-17 Compuestos de tetrahidroisoquinolinil-carboxamida y composiciones que los contienen CO5080731A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB9726695.1A GB9726695D0 (en) 1997-12-17 1997-12-17 Novel compounds

Publications (1)

Publication Number Publication Date
CO5080731A1 true CO5080731A1 (es) 2001-09-25

Family

ID=10823780

Family Applications (1)

Application Number Title Priority Date Filing Date
CO98075174A CO5080731A1 (es) 1997-12-17 1998-12-17 Compuestos de tetrahidroisoquinolinil-carboxamida y composiciones que los contienen

Country Status (30)

Country Link
US (1) US6248754B1 (es)
EP (1) EP1042296B1 (es)
JP (1) JP2002508360A (es)
KR (1) KR20010033194A (es)
CN (1) CN1125052C (es)
AP (1) AP2000001832A0 (es)
AR (1) AR014942A1 (es)
AT (1) ATE260258T1 (es)
AU (1) AU744451B2 (es)
BG (1) BG104607A (es)
BR (1) BR9813642A (es)
CA (1) CA2315079A1 (es)
CO (1) CO5080731A1 (es)
DE (1) DE69821988T2 (es)
EA (1) EA200000657A1 (es)
ES (1) ES2216333T3 (es)
GB (1) GB9726695D0 (es)
HU (2) HUP0000987A3 (es)
ID (1) ID24810A (es)
IL (1) IL136382A0 (es)
MA (1) MA26583A1 (es)
NO (1) NO315649B1 (es)
NZ (1) NZ504706A (es)
OA (1) OA11526A (es)
PE (1) PE20000006A1 (es)
PL (1) PL341222A1 (es)
SK (1) SK9142000A3 (es)
TR (1) TR200001791T2 (es)
WO (1) WO1999031068A1 (es)
ZA (1) ZA9811503B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010016657A1 (en) * 1997-03-18 2001-08-23 Smithkline Beecham P.L.C. Substituted isoquinoline derivatives and their use as anticonvulsants
WO1999016752A1 (en) * 1997-09-30 1999-04-08 Molecular Designs International, Inc. β3-ADRENORECEPTOR AGONISTS, AGONIST COMPOSITIONS AND METHODS OF USING
GB9915589D0 (en) * 1999-07-02 1999-09-01 Smithkline Beecham Plc Novel compounds
AU1734401A (en) * 1999-12-09 2001-06-18 Mitsubishi Pharma Corporation Carboxyamido derivatives
US6593341B2 (en) 2001-03-29 2003-07-15 Molecular Design International, Inc. β3-adrenoreceptor agonists, agonist compositions and methods of making and using the same
US7173032B2 (en) 2001-09-21 2007-02-06 Reddy Us Therapeutics, Inc. Methods and compositions of novel triazine compounds
US6596734B1 (en) 2002-10-11 2003-07-22 Molecular Design International, Inc. Tetrahydroisoquinoline compounds for use as β3-adrenoreceptor agonists
US7119214B2 (en) * 2004-04-13 2006-10-10 Cephalon France Thio-substituted tricyclic and bicyclic aromatic methanesulfinyl derivatives
GB0619176D0 (en) * 2006-09-29 2006-11-08 Lectus Therapeutics Ltd Ion channel modulators & uses thereof
TWI459947B (zh) 2007-06-26 2014-11-11 Otsuka Pharma Co Ltd 苯并氮呯化合物及藥學製劑

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4022900A (en) * 1970-09-09 1977-05-10 Marion Laboratories, Inc. Compositions containing 1,2,3,4-tetrahydroisoquinolines used as hypotensive agents
CZ416498A3 (cs) * 1996-06-17 1999-06-16 Smithkline Beecham Plc Substituovaný benzamidový derivát a jeho použití jako antikonvulsantu
CA2284218A1 (en) 1997-03-18 1998-09-24 Smithkline Beecham P.L.C. Substituted isoquinoline derivatives and their use as anticonvulsants

Also Published As

Publication number Publication date
PL341222A1 (en) 2001-03-26
MA26583A1 (fr) 2004-12-20
ZA9811503B (en) 2000-06-15
GB9726695D0 (en) 1998-02-18
EA200000657A1 (ru) 2000-12-25
NO20003142D0 (no) 2000-06-16
AR014942A1 (es) 2001-04-11
HUP0000987A3 (en) 2000-10-30
EP1042296B1 (en) 2004-02-25
BG104607A (bg) 2001-02-28
AU1572499A (en) 1999-07-05
HUP0000987A2 (hu) 2000-09-28
ID24810A (id) 2000-08-24
KR20010033194A (ko) 2001-04-25
CA2315079A1 (en) 1999-06-24
HUP0004663A2 (hu) 2001-05-28
DE69821988T2 (de) 2005-01-05
AU744451B2 (en) 2002-02-21
JP2002508360A (ja) 2002-03-19
ATE260258T1 (de) 2004-03-15
OA11526A (en) 2004-02-09
NO20003142L (no) 2000-06-16
SK9142000A3 (en) 2000-11-07
WO1999031068A1 (en) 1999-06-24
EP1042296A1 (en) 2000-10-11
HUP0004663A3 (en) 2002-10-28
BR9813642A (pt) 2000-10-17
IL136382A0 (en) 2001-06-14
CN1284946A (zh) 2001-02-21
NZ504706A (en) 2002-11-26
US6248754B1 (en) 2001-06-19
TR200001791T2 (tr) 2000-12-21
AP2000001832A0 (en) 2000-06-30
PE20000006A1 (es) 2000-03-01
NO315649B1 (no) 2003-10-06
DE69821988D1 (de) 2004-04-01
CN1125052C (zh) 2003-10-22
ES2216333T3 (es) 2004-10-16

Similar Documents

Publication Publication Date Title
CA2284732A1 (en) Analogs of cocaine
BG104561A (en) Aryl fused azapolycyclic compounds
ZA982134B (en) Therapeutic agents.
JP2005502680A5 (es)
NO20024042D0 (no) Aryl-fusjonerte azapolysykliske forbindelser
CO5080731A1 (es) Compuestos de tetrahidroisoquinolinil-carboxamida y composiciones que los contienen
AU2002239463A1 (en) Cyclopenta(b)(1,4) diazepino(6,7,1-hi)indoles as 5ht2c antagonists
MY129473A (en) 3,3-diarylpropylamines, their use and preparation
BG104983A (en) Aryl fused azapolycyclic compounds
ZA943241B (en) Therapeutic agents
PL312251A1 (en) Isoquinoline derivatives as therapeutic agents
SI1645558T1 (sl) Piperazinilpirazini kot modulatorji serotonin 5-HT2C receptorja
AR018656A1 (es) Compuesto de tetrahidronaftiridinil-carboxamida, composicion farmaceutica que lo contiene, su uso para la manufactura de un medicamento y procedimientopara su preparacion
DE69925160D1 (de) Arylpiperidin- und aryl-1,2,5,6-tetrahydropyridinamid-derivate mit 5ht1a rezeptor aktivität
RU2221786C2 (ru) Производные тетрагидроизохинолиналканола, способы лечения и фармацевтические композиции на их основе
ES2119454T3 (es) Derivados de pirrolidina para el tratamiento de los desordenes relacionados con la csk y la gastrina.
JO1809B1 (en) Therapeutic agents
JO1815B1 (en) Therapeutic agents
ECSP972216A (es) Antagonistas muscarinicos